BCA
ADMS

Berman Capital Advisors’s Adamas Pharmaceuticals ADMS Stock Holding History

Berman Capital Advisors’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-104
Closed – – 1632
2019
Q1 		$0 Buy
+104
New +$935 ﹤0.01% 1529

Other funds holding ADMS

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Berman Capital Advisors's ADMS Position: Q2 2019 in Review

Berman Capital Advisors sold out of Adamas Pharmaceuticals (ADMS) in Q2 2019, closing a stake of 104 shares.

Berman Capital Advisors first reported a position in ADMS in Q1 2019 and held it in 1 quarter. The position peaked at $0 in Q1 2019. 78 funds tracked by Wall St. Rank hold ADMS as of Q2 2019.

  • Berman Capital Advisors reported no remaining Adamas Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Berman Capital Advisors sold 104 Adamas Pharmaceuticals shares in Q2 2019.
  • Berman Capital Advisors first reported a position in Adamas Pharmaceuticals in Q1 2019 and held it in 1 quarter.
  • Berman Capital Advisors's Adamas Pharmaceuticals position peaked at $0 in Q1 2019.
  • 78 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q2 2019.

Based on Berman Capital Advisors's 13F filing for Q2 2019, filed 30 Jul 2019.